While logistical questions remain about remote patient monitoring (RPM), its benefits for both patients and caregivers are abundantly clear.
Although the way pulmonologists both treat and define PFF has evolved, the clinician’s role in identifying when pulmonary fibrosis becomes progressive is still a critical aspect of care.
In a featured episode of Cleveland Clinic’s Respiratory Exchange podcast, Daniel Culver, DO, discusses the evolution in classification, diagnosis, treatment and management of interstitial lung disease.
Systemic treatment is often warranted as mechanic’s hands may be the most visible but not the only manifestation of antisynthetase syndrome.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
A patient with common variable immunodeficiency, lung nodules and lymphadenopathy with potential for lymphoma requires a multidisciplinary approach.
Compared with placebo, inhaled treprostinil was associated with lower risk of clinical worsening and fewer exacerbations of underlying lung disease during a 16-week treatment period.
A multidisciplinary approach can uncover unsuspected diagnoses of interstitial lung disease. Many times this precision makes a difference in management strategy and patient outcomes.
Patients with COVID-19 who have underlying chronic lung disease are at increased risk for developing severe illness. Pulmonologist Brian Southern, MD, recently authored a review article in Cleveland Clinic Journal of Medicine’s COVID-19 Curbside Consults series. In this article, he takes a closer look at what is known about ILD and sarcoidosis in the context of the pandemic and offers insights for managing care.
Mild symptoms and a quick recovery are common in most cases of sarcoidosis, but a minority of patients have significant morbidity and impaired quality of life because of multiorgan involvement. A new Cleveland Clinic study examines association between income and sarcoidosis outcomes, after controlling for socioeconomic and disease-related factors.
Kristin Highland, MD, discusses new potential pathways to treat scleroderma-associated interstitial lung disease.